: iStockAnalyst.com Symbols Feed

Health Care Tops News This Morning: XOMA, CEPH, VVUS, CLZR, ELOS

Wed, 09 Sep 2009 16:50:01 GMT

The healthcare stocks remained in focus on Wednesday ahead of President Obama’s speech tonight on his healthcare reform effort. The healthcare space also witnessed heightened activity amid a flurry of corporate news.[More...]

The Week In Review: Biopharma News Back In The Forefront

Sun, 23 Nov 2008 16:19:00 GMT

ChinaBio® Accelerator will hold the ChinaBio® Partnering Forum on June 3 and 4, 2009 in Shanghai; Chiral Quest raised $13 million in a Series B financing from China-based venture capitalists; GSK and Shenzhen Neptunus Interlong will work towards a JV that develops flu vaccines; BMP Sunstone has acquired rights to the Runchang capsule, a liquid-filled hard capsule; Syneron Medical has established a JV to market its medical aesthetic devices in China; China Medical Technologies has developed two molecular diagnostic kits to detect EFGR abnormalities; big pharma continues to make investments in China; China Medical Technologies released positive Q2 results, Genesis Pharmaceuticals reported that Q1 revenues and earnings climbed significantly; Lotus Pharma said its Q3 net income climbed even though revenues dropped slightly; Sinovac Biotech reported that revenue and profits declined in Q3; and China Shenghuo Pharmareleased its Q3[More...]

Analyst Comments: Lawson, Hawaiian Electric, Allied Irish Banks, Qualcomm, PMI Group, RAIT Financial, Ford Motor, Johnson & Johnson, Syneron

Tue, 17 Jun 2008 17:01:54 GMT

Lawson Software, Inc. (LWSN) is a leading provider of enterprise resource planning (ERP) software solutions and professional services to mid-market enterprises in the health care, retail, public and professional service industries. The company reported revenues of $212.9 million in Q3:FY08, missing our estimate of $218 million while non-GAAP EPS of $0.08 came in line with our expectations. We maintain our Hold rating on the shares. Lawson...[More...]

Israeli Inflation Surges: What Should Investors Do?

Fri, 16 May 2008 15:32:25 GMT

Aaron Katsman[More...]

Premarket Report

Thu, 15 May 2008 13:35:37 GMT

Good morning. We're starting out the day with a positive bias amid some restructuring news at General Electric (GE) and a proxy battle at Yahoo! (YHOO). On the economic front, investors didn't show much reaction to a slightly higher than expected jobless[More...]

Hedge Fund Masters 2008...Everyone Loves Qualcomm

Mon, 25 Feb 2008 17:41:21 GMT

Feeling a little contrarian today? Seth Klarman is, and he is buying some beaten down SLM with a full third of his portfolio. . .The 13Fs are arriving and below I update the two tracking portfolios.(For background on this approach, check out [More...]

Hedge Fund Masters

Fri, 16 Nov 2007 18:31:08 GMT

Will looking under the hedge fund hood reveal investment gems - or are you driving by looking in the rear view mirror?The 13Fs are arriving and it is that time again - time to look under the hood and see what all the top hedge funds are up to. This post is particularly timely as my truck just blew a gasket and I am now carless.(For background on this approach, check out the following links -

[More...]

Syneron Medical Ltd. And Candela Corporation to Merge Creating a Leading Global Aesthetic Device Company

Wed, 09 Sep 2009 09:47:00 GMT

Syneron Medical Ltd. (NASDAQ:ELOS) and Candela Corporation (NASDAQ:CLZR) announced today that they have entered into a definitive agreement to combine the companies in an all stock transaction.
There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the ability of each of Candela Corporation and Syneron Medical Ltd. to satisfy the closing conditions and consummate the transaction, including obtaining the approval of the transaction by Candela Corporation's stockholders; the risk that the businesses may not be integrated successfully; the risk that the transaction may involve unexpected costs or unexpected liabilities; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the transaction make it more difficult to maintain relationships with customers, employees, or suppliers; and the other risks set forth in Candela Corporation and Syneron Medical Ltd.'s most recent Annual Report on Form 10-K and Form 20-F, respectively, as well as the other factors described in the filings that Candela Corporation and Syneron Medical Ltd. make with the SEC from time to time.
If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Candela Corporation and Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

[More...]

Real Housewives of Orange County Star Gretchen Rossi Reveals Next and Best in Beauty Live from the World's Most Exclusive Aesthetics Conference

Tue, 25 Aug 2009 14:05:00 GMT

Gretchen Rossi, star of the Bravo reality show hit the 'Real Housewives of Orange County', will report live on the latest in beauty advancements from the 5-Continent Congress in Nice, France, Sept. 10-12. Bringing physicians, consumers and media the latest global trends in aesthetic products and treatments all as-it-happens, http://gretchenproject.com will feature Twitter updates and video and audio interviews with attendees from the event.[More...]

Syneron Reports Second Quarter 2009 Results

Thu, 13 Aug 2009 10:50:00 GMT

Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announced financial results for the second quarter ended June 30, 2009.
Syneron's gross margins rose to 64.8% in the second quarter, compared to 58.1% in the first quarter of 2009 and 54.7% in the fourth quarter of 2008.
Commenting on the results and developments in the second quarter, Syneron CEO Lou Scafuri said, "I am pleased with the steady improvement in our results since the start of 2009, particularly with the improvements in margins which can be attributed directly to the success of the restructuring program in streamlining costs across the company.

[More...]

Syneron Medical to Announce Second Quarter 2009 Financial Results on August 13th, 2009

Mon, 03 Aug 2009 12:25:00 GMT

YOKNEAM, ISRAEL -- -- 08/03/09 -- Syneron Medical Ltd. , an innovator in the development, marketing and sales of elos combined-energy medical aesthetic devices, today announced that it will release its financial results for the second quarter of 2009 before market opening on Thursday, August 13, 2009. The earnings release will be available on Syneron's website at www.syneron.com.[More...]

Syneron Medical to Present at the Gabelli & Company Small Cap Healthcare Conference and the Needham Growth Conference

Thu, 04 Jun 2009 18:25:00 GMT

YOKNEAM, ISRAEL -- -- 06/04/09 -- Syneron Medical Ltd. , an innovator in the development, marketing and sales of elos combined-energy medical aesthetic devices, announced today that Syneron will participate in the Gabelli & Company Small Cap Healthcare Conference on Tuesday, June 9, 2009 and in the Needham Growth Conference on Wednesday, June 10, 2009, both in New York. Syneron CEO, Lou Scafuri, will present on behalf of Syneron at 9:30am ET in the Gabelli & Company Small Cap Healthcare Conference and at 8:00am ET in the Needham Growth Conference.[More...]

Syneron to Launch Industry-First Treatment Modality, New Product for Procedures Leading to Body Contouring and Physician-Focused Initiative at THE Aesthetics Show

Wed, 03 Jun 2009 12:56:00 GMT

YOKNEAM, ISRAEL and IRVINE, CA -- -- 06/03/09 -- Syneron Medical Ltd. , http://www.syneron.com, a leading innovator in medical aesthetic devices, will unveil three groundbreaking initiatives at THE Aesthetic Show in Las Vegas, June 5-7. The company will introduce a new and unique treatment modality called Sublative Rejuvenation, which answers the skin rejuvenation market's emerging demand for optimal efficiency, minimal downtime and an affordable procedure price point. In addition, Syneron will release VelaShape II, with increased RF energy for quicker non-invasive procedures leading to body contouring, and launch Syneron Advantage -- a new physician partnership program to support customers' financial and business needs in today's economic climate.[More...]

Gabelli & Company, Inc.’s Healthcare Symposium

Wed, 03 Jun 2009 12:00:00 GMT

Gabelli & Company, Inc. will host a Healthcare Symposium on Tuesday, June 9, 2009 at the Sofitel New York. This investment research meeting will include presentations from senior management of various dental, dermatology, and specialty healthcare manufacturers and distributors. Institutional investors should contact their salesperson for more information or to register.[More...]

Syneron Reports First Quarter 2009 Results

Thu, 14 May 2009 10:48:00 GMT

Syneron Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announced financial results for the first quarter ended March 31st, 2009.
Syneron recorded a net loss in the first quarter of $8.2 million on a GAAP basis, compared to a net loss of $15.9 million in the fourth quarter of 2008 and a net profit of $8.3 million in the first quarter of 2008.
The non-GAAP result for the first quarter is equivalent to a loss of $0.23 per basic and diluted share, compared to a fourth quarter loss in 2008 of $0.50 per basic and diluted share and earnings per share of $0.37 in the first quarter of 2008.

[More...]